Objective: A meta-analysis of the studies involving Sacubitril/Valsartan in chronic heart
failure was performed to compare the efficacy and safety of Sacubitril/Valsartan with …

Aims Sacubitril/valsartan improves morbidity and mortality in patients with heart failure and
reduced ejection fraction (HFrEF). Whether initiation of sacubitril/valsartan limits the use and …

The quality of evidence regarding patient-centered outcomes in adults with heart failure (HF)
after sacubitril combined with valsartan has not been systematically appraised. We searched …

Background Angiotensin receptor and neprilysin inhibition (ARNI) has been shown to
reduce cardiovascular mortality by 20% as compared with enalapril in a randomized …

Current guidelines recommend angiotensin receptor blocker neprilysin inhibitors
(ARNI)(sacubitril/valsartan) as a replacement for angiotensin-converting-enzymeinhibitor …

Conclusion Although the totality of scientific evidence supports sacubitril/valsartan as having
incremental efficacy over valsartan in a broad population of patients with HF and EF> 40 …

Background Sacubitril/valsartan has been highly efficacious in randomized clinical trials of
patients with HFrEF. However, the effectiveness of sacubitril/valsartan in routine US clinical …

Aims We systematically reviewed the European real‐world evidence (RWE) about sacubitril‐
valsartan for heart failure with reduced ejection fraction. Methods and results Twenty‐one …

Background To observe the changes of cardiac structure and function in elderly patients with
heart failure with reduced ejection fraction (HFrEF) after taking Sacubitril-Valsartan for 6 …

Background: Sacubitril/valsartan is a combination drug therapy for heart failure (HF) patients
that has been shown to reduce mortality and hospitalisation. Aims: To explore clinically …